The objective of the study is to test a relatively small set of 59 carefully selected top ranking prognostic marker genes on a large panel of primary untreated neuroblastoma tumours and to look for a predictive difference in gene-expression between the neuroblastoma samples from uniformly treated patients that relapsed/died and those from the event-free survivors within the same risk groups.